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A practice-based randomized controlled
trial to improve medication adherence
among Latinos with hypertension: study
protocol for a randomized controlled trial
Antoinette Schoenthaler1*, Franzenith De La Calle1, Miguel Barrios-Barrios1, Aury Garcia1, Maria Pitaro2,
Audrey Lum2 and Milagros Rosal3
Abstract
Background: Latinos experience disproportionately higher rates of uncontrolled hypertension as compared to
Blacks and Whites. While poor adherence is a major contributor to disparities in blood pressure control, data in
Latino patients are scant. More importantly, translation of interventions to improve medication adherence in
community-based primary care practices, where the majority of Latino patients receive their care is non-existent.
Methods: Using a randomized controlled design, this study evaluates the effectiveness of a culturally tailored,
practice-based intervention compared to usual care on medication adherence, among 148 Latino patients with
uncontrolled hypertension who are non-adherent to their antihypertensive medications. Bilingual medical assistants
trained as Health Coaches deliver the intervention using an electronic medical record system-embedded adherence
script. Patients randomized to the intervention group receive patient-centered counseling with a Health Coach to
develop individualized self-monitoring strategies to overcome barriers and improve adherence behaviors. Health
Coach sessions are held biweekly for the first 3 months (6 sessions total) and then monthly for the remaining 3
months (3 sessions total). Patients randomized to the usual care group receive standard hypertension treatment
recommendations as determined by their primary care providers. The primary outcome is the rate of medication
adherence at 6 months. The secondary outcome is reduction in systolic and diastolic blood pressure at 6 months.
Discussion: If successful, findings from this study will provide salient information on the translation of
culturallytailored, evidence-based interventions targeted at medication adherence and blood pressure control into
practice-based settings for this high-risk population.
Trial registration: NCT01643473 on 16 July 2012.
Keywords: Medication adherence, Hypertension, Latinos, Health coach
Background
Latinos are the fastest growing ethnic group of the
United States (US) and account for more than half of
the total increase in the country’s population over the
past decade [1]. This growth has been accompanied by a
significant increase in cardiovascular disease (CVD)-
related morbidity and mortality [2]. Despite increasing
trends in the awareness and treatment of hypertension
(HTN) among all groups, Latinos have the lowest blood
pressure (BP) control rates in the US [3]. Although
barriers to optimal HTN control, such as poor access
and low awareness, have been used to explain the dis-
parities in BP control between Latinos and Whites, BP
control rates remain lower among Latinos who receive
treatment compared to Whites [4]. This enigma may be
explained by the disproportionately poorer adherence to
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prescribed antihypertensive medications among Latinos
compared to Whites [5, 6].
Poor medication adherence is a major contributor to
inadequate BP control, and is associated with 125,000
deaths annually [7]. While many interventions address
poor adherence behaviors in hypertensive patients [8, 9],
data in Latino patients are scant. More importantly,
translation of adherence interventions to community-
based primary care practices, where the majority of
Latino patients receive care, is non-existent. Thus, the
development of tailored interventions that target
improving medication adherence in this high-risk popu-
lation is needed in order to address the racial disparities
in BP control between Latinos and Whites.
The Ayudando Latinos Hipertensos Para Mejorar
Adherencia a los Medicamentos (ALMA) trial addresses
this gap in the literature by evaluating the effect of a cul-
turally tailored, practice-based intervention on medica-
tion adherence in 148 Latino patients with uncontrolled
HTN, who are non-adherent to their antihypertensive
medications and followed in a medical clinic in New
York City. To facilitate translation into routine practice,
the intervention is embedded into the clinic’s electronic
medical record (EMR) system, and bilingual medical
assistants (MAs) who are trained as Health Coaches de-
liver the patient-centered counseling.
Study aims
The primary aim of the ALMA trial is to evaluate the ef-
fect of a culturally tailored, evidence-based adherence
intervention (AI), delivered by bilingual Health Coaches
versus usual care (UC), on medication adherence at 6
months among 148 Latino patients with uncontrolled
HTN, who are non-adherent to their anti-hypertensive
medications. The secondary aim is to evaluate the effect
of the AI versus UC on BP reduction at 6 months. We
hypothesize that the AI group will have a higher propor-
tion of patients who are adherent to their antihyperten-
sive medication; and a greater reduction in systolic BP
(SBP) and diastolic BP (DBP) at 6 months as compared
to the UC group. ALMA is one of the first trials to
evaluate the effect of a culturally tailored, practice-based
AI for Latinos with uncontrolled HTN. Moreover,
trained MAs who assume the role of a Health Coach,
and who often are the frontline healthcare workers in
primary care practices, deliver the intervention; thus
maximizing the likelihood of translating the study into
clinical practice.
Fig. 1 Flow of participants through the study
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Methods
Study design
As depicted in Fig. 1, ALMA is a randomized controlled
trial with 2 arms: a culturally tailored, practice-based AI
arm, and a UC arm. Approximately 148 Latino patients
with uncontrolled HTN and who are non-adherent to
their antihypertensive medications are randomly assigned
equally to either the AI or UC conditions. Patients ran-
domized to the UC group receive standard HTN treat-
ment recommendations as determined by their primary
care providers (PCPs). Patients randomized to the AI
group participate in 6 biweekly sessions with bilingual
Health Coaches for the first 3 months and then 3 monthly
sessions for the remaining 3 months (9 sessions total).
Health Coaches utilize a culturallytailored adherence
script to identify patient’s specific medication adherence
barriers and to explore medication adherence facilitators.
Based on the patients’ responses, the Health Coach then
engages in targeted patient-centered counseling to assist
patients in developing individualized self-monitoring strat-
egies to overcome these barriers and improve adherence
behaviors. Brief motivational interviewing (MINT) strat-
egies form the basis of the adherence counseling. MINT is
a patient-centered counseling approach that encourages
patients to express their concerns about, and barriers to,
taking medications, connect their personal values and
goals to their health behaviors, enhance their motivation
and confidence for change, and make a commitment to
change [10]. We have previously demonstrated the
effectiveness of using brief MINT to improve medication
adherence in Black hypertensive patients followed in
community-based practices [11].
Study assessments are conducted at baseline, 1 month
post-baseline (visit 1), 3 months post the 1-month as-
sessment (visit 2), and 6 months post the 1-month as-
sessment (visit 3). The primary and secondary outcomes
are assessed at the 3-month (visit 2) and 6-month (visit
3) follow-up visit. Patients receive US$5 at baseline,
US$10 at the 1-month visit, US$10 at the 3-month visit,
and US$10 at the completion of the 6-month visit (total
of US$35 over the 6-month study).
Study setting and patients
This study is conducted at a community-based medical
clinic that serves predominantly Latino patients in New
York City. The clinic employs 12 bilingual primary care
providers, and 75 bilingual support and administrative
staff (including 28 MAs and 7 Health Coaches). An Aca-
demic Community Advisory (ACA) Board comprised of
four members of the clinic, each representing a key
stakeholder group (i.e., patients, clinic staff, and clinic
administrators), provides input throughout the study on
recruitment, delivery of the intervention and on how
best to retain patients.
The target enrollment for the study is 148 patients
who meet the following study eligibility criteria: a) have
uncontrolled HTN defined as BP > 140/90 mmHg on at
least 2 consecutive visits in the past year of receiving
care at the clinic (or BP > 130/80 mmHg for those with
diabetes or kidney disease) and at least 1 CVD risk fac-
tor including hyperlipidemia or diabetes; b) take at least
1 antihypertensive medication; and c) self-identify as
Latino and be ≥ 18 years of age. Patients are excluded if
they: a) refuse or are unable to provide informed con-
sent; b) currently participate in another HTN study; or
c) have significant psychiatric comorbidity. The study
protocol was reviewed and approved by the Institutional
Review Board of New York University Langone Medical
Center. All patients provide written informed consent to
participate. The study is registered at www.clinicaltrials.
gov: NCT01643473.
Recruitment
Potentially eligible patients are identified via three
methods. First, PCPs and their MAs refer patients who
meet the eligibility criteria to a research assistant (RA).
Referrals are done via EMR flags, or by calling the RA.
The RA then conducts an onsite screening and consent
visit with the referred patients. Second, the RA reviews
the EMR using the International Classification of Dis-
eases (ICD)-9 codes for the diagnosis of HTN (401–
401.9). The PCPs of patients are notified of their poten-
tial eligibility and asked permission to enroll their
patients into the study. Upon obtaining PCP consent,
the RAs note the eligible patients’ appointment dates
and approach the patients at their next clinic visit for
screening and consent. Finally, flyers are also hung in
the clinic waiting room.
Randomization
After completion of the 1-month (post-baseline) visit,
patients who are non-adherent to their prescribed anti-
hypertensive medication (defined as having a Morisky
Score ≥ 3) are randomly assigned to either the AI or UC
group by the study statistician. Block randomization is
used to ensure a roughly equal assignment of patients to
the two groups. A block size of 8 or 16 varies randomly
across the trial, with the investigators blind to the block
size. All randomized subjects will be included in the ana-
lyses using intent-to-treat strategies [12]. Following Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines [13, 14], the randomization group names are
kept in opaque envelopes in a locked cabinet away from
the study site. Once a month, the study coordinator
opens the envelopes to reveal patients’ group assign-
ment. A RA informs patients of their group assignment
by phone; at which time, they also discuss the telephone
counseling schedule, if randomized to the AI arm and
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answers any additional questions. As is true for most be-
havioral interventions, neither the patient nor the
interventionists (Health Coaches) or study staff can be
blinded to the group assignment. To mitigate the poten-
tial for bias for the primary and secondary outcomes, an
electronic monitoring device (EMD) is used to assess
medication adherence and a validated automated BP
device is used to assess BP.
Description of the intervention
Development of the Adherence Intervention (AI)
The Common Sense Model of Self-regulation (CSM) is
the theoretical framework underlying the AI. The CSM
incorporates patients’ illness beliefs about the cause,
symptoms, consequences, controllability, and timeline
(acute versus chronic) of their condition into the
conceptualization of adherence behaviors [15]. More-
over, given the dynamic nature of medication-taking be-
haviors over time, the five CSM illness beliefs are further
categorized using Vrijens et al. medications adherence
taxonomy [16, 17] into: initiation, implementation, and
discontinuation of the recommended treatment plan.
Initiation refers to patients’ willingness to take their
medications as well as the perceived benefits and risks of
the medications. Implementation is a continuous process
that assesses how well patients’ daily medication-taking
behaviors correspond to the prescribed regimen. Finally,
discontinuation refers to early termination of the medi-
cation regimen by the patient.
These conceptual frameworks, in combination with a
review of the published literature that examines the role
of patients’ illness beliefs on adherence behaviors among
Latinos with chronic diseases (i.e., diabetes, HIV), and
preliminary results from our previous studies, formed
the initial basis of the illness beliefs and adherence
barriers addressed by the AI.
A formative phase was conducted during the first 8
months of the study, prior to the initiation of the trial
and subject recruitment, to further refine the AI. Specif-
ically, data from the focus groups and cognitive patient
interviews, as well as feedback from the ACA Board
were obtained to gain an accurate understanding of the
multiple determinants of medication adherence (i.e., cul-
tural, cognitive, psychosocial, behavioral, logistical) dir-
ectly from the target patient population as well as the
key stakeholders that deliver services to them. Overall,
the findings showed that Latino patients form their be-
liefs about HTN and HTN medications with information
received from family members, media, and to a lesser
extent, physicians. Moreover, in spite of the fact that
HTN was perceived as a treacherous and unpredictable
disease, and medications were deemed an essential method
to avoid adverse consequences, the need for medications
was determined by the presence of perceived symptoms.
Symptom alleviation was used as a marker for treatment
efficacy and HTN-related risk reduction. Based on the
focus group findings, a rubric for adherence counseling
was developed to assist the Health Coaches in delivering
the intervention. Specifically, the AI script encompasses a
set of guidelines for counseling patients based on changes
in their adherence behaviors overtime (i.e., improving
adherence, or no change/worse adherence) and barriers
and facilitators to medication adherence informed by
findings from the focus groups.
To ensure consistency in the delivery of the interven-
tion across English-speaking and Spanish-speaking
Latino patients, the AI was further translated into the
Spanish language by a professional translation service.
Three semi-structured interviews were then conducted
with bilingual Latino patients to garner feedback on the
clarity of the English and Spanish versions of the AI, and
to elicit additional culture-specific norms regarding initi-
ation and implementation of the medication regimen,
barriers to adherence, and specific strategies for develop-
ing behavioral action plans for taking medications as pre-
scribed. The interviews lasted approximately 30 minutes
and patients receive US$15 for their time. Finally, the
ACA Board provided feedback on the cultural appropri-
ateness of the AI and offered insight into the logistical and
administrative barriers that can impede adherence in this
population. Together, these data were used to further
refine the AI to match the literacy and cultural needs of
the Latino patient population at the clinic, and to inform
important intervention messages during the delivery of
the counseling sessions.
Integration of the finalized AI into the EMR
The final AI was customized for the clinic’s EMR-system
using a format similar to the clinic’s current educations
materials and EMR templates (Fig. 2). This allows for
standardization of procedures and tracking of patient
progress. In addition, the EMR-embedded AI allows
Health Coaches to systematically record patients’ re-
sponses and retrieve information and progress from pre-
vious sessions. It also includes tips for using MINT
strategies to address patient barriers such as eliciting
and responding to patients’ understanding of the causes,
complications and treatment of HTN; perceived barriers
to taking medications; and strategies for adoption of
adherence behaviors. Thus, based on the patient’s re-
sponses, the Health Coach can engage in targeted pa-
tient-centered counseling to assist patients in developing
individualized self-monitoring strategies to overcome bar-
riers and improve adherence behaviors. Customization of
the AI into the EMR also facilitates the integration of the
intervention into the clinic workflow once the study has
ended. Access to the AI is via a password-protected
portal.
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In order to minimize contamination of the UC group,
several quality control measures were embedded in the
EMRs. Upon randomization, patients’ EMRs are
marked according to their group assignment. Health
Coaches are not able to access the EMR adherence
script for patients randomized to the UC arm, thereby
preventing the utilization of the intervention with these
patients. Moreover, Health Coaches are required by the
clinic to document everything discussed in their ses-
sions; thus, we will be able to review their notes to de-
termine whether medication adherence was discussed
with patients in the UC group and to what extent. As a
secondary measure, at follow-up visits, contamination
is measured based on patients’: 1) awareness of both
study arms, 2) direct exposure to the intervention activ-
ities among those in the control arm, and 3) the nature
of any contact and interaction with patients in the
intervention arm.
Health coach training
As part of the standard of care at the participating clinic,
all MAs undergo training in chronic disease manage-
ment, development of effective communication skills,
and principles of self-management and behavior change.
The trainings include didactic and interactive sessions,
direct observation, and skills assessment. Upon comple-
tion of the training, the MAs are promoted to Health
Coaches, at which point they can deliver individual ses-
sions with patients. A Health Coach’s typical clinic re-
sponsibilities include reviewing the daily panel of
patients with the PCP in a morning huddle; scheduling
appointments for telephone follow-up of test results;
providing general health education; communicating to
the patient, recommendations for treatment changes
made by the PCP; seeing patients for BP checks and, if
needed, referring the patient to the PCP for medication
adjustment. Since patient visits with Health Coaches are
Fig. 2 Example of Electronic Medical Record (EMR)-embedded adherence intervention template
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standard of care at the clinic, regardless of group assign-
ment; all patients have contact with a Health Coach.
For the purpose of this study, four of the seven Health
Coaches employed at the clinic received additional train-
ing in the delivery of the tailored AI and patient-cen-
tered counseling techniques 1 month prior to initiation
of the intervention. The 3-day interactive training in-
cluded an overview of the project goals and study over-
view; an introduction to the facilitators and barriers of
medication adherence in Latinos; and overview of self-
monitoring strategies (i.e., use of reminder systems) to
improve adherence. In addition, Health Coaches re-
ceived an introduction to the basic principles of MINT
techniques and problem-solving strategies [10] and also
had the opportunity to practice the MINT strategies that
form the basis of the intervention through role-plays
and self-modeling with feedback from members of the
MINT International Network of Trainers. Finally, the
Health Coaches received an in-depth education on the
content of the AI materials and practice sessions on the
use of the EMR AI template and how to develop action
plans through structured goal setting.
Adherence Intervention (AI) contacts
Patients randomized to the AI group participate in 9 ses-
sions (6 biweekly sessions for the first 3 months, and
then 3 monthly sessions for the remaining 3 months)
with the trained bilingual Health Coaches who utilize
the culturally tailored AI to identify patient’s specific
medication adherence barriers and facilitators. Patient’s
patterns of non-adherence, which are assessed during
the baseline and 1-month study visit are also provided to
the Health Coaches prior to the start of the intervention.
Each counseling session lasts approximately 15 minutes
and is conducted via telephone or in-person.
Usual Care (UC) condition
Patients randomized to the UC group receive standard
HTN treatment recommendations as determined by
their PCP as well as the standard health coaching proce-
dures followed at the clinic.
Outcomes assessments
Study assessments for primary and secondary outcomes
are completed at baseline, 3 months (post the 1-month
visit), and 6 months (post the 1-month visit). All assess-
ments are performed by trained RAs and include: (1) ob-
jective measures; (2) physiological measures, (3) self-
report measures, and (4) EMR chart data. Table 1 sum-
marizes the measures according to their timeline.
Primary outcome
Medication adherence
The primary outcome is the rate of medication adher-
ence at the 6-month study visit, assessed using electronic
drug monitoring devices (EMD; Information Mediary
Table 1 Study measures by modality
Measures Baseline 1 Month 3 Months 6 Months
Outcome measures
Blood pressure measurements X X X
Medication adherence (Electronic Monitoring Device (EMD)) X X X
Self-report measures
Participant demographics X
Cognitive functioning (CARE-DIAG) X
Health literacy X
Medical comorbidity (Charlson Comorbidity Index) X X
Self-efficacy scale (MASE) X X X
Intrinsic motivation (TSRQ) X X X
Illness beliefs (IPQ-R) X X X
Medication adherence (Morisky eight-item) X X X
Attitudes about medication (Beliefs about Medication Questionnaire) X X X
EMD diary X X
EMD survey X X
PCAS survey X X
Electronic medical record data
Chart review X X
CARE-DIAG Comprehensive Assessment and Referral Evaluation Dementia Diagnostic Scale, IPQ-R Illness Perceptions Questionnaire-revised, MASE Medication
Adherence Self-Efficacy Scale, PCAS Primary Care Assessment Survey, TSRQ Treatment Self-Regulation Questionnaire
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Co.). EMDs are designed as pill bottles with an elec-
tronic chip in the cap that records a temporal history of
the date, time, and interval between each dosing, thereby
allowing for real-time tracking of adherence behaviors.
Medication adherence rates by the EMD are calculated
as the percent of prescribed doses removed by the pa-
tient during the study monitoring period using the
formula:
Number of doses removed=Number of doses prescribed
 100
In essence, this metric (known as taking adherence), is
the proportion of days on which the patient took his or
her medication as prescribed, divided by the total num-
ber of days that he or she is expected to take them
(number of days in the assessed time period).
Detailed records of all patient emergency room visits
and hospitalizations are kept to avoid erroneously penal-
izing patients for missing values for days during the
study when their EMD is not in use. Such days are re-
moved from the denominator of the formula in estimat-
ing the adherence rates for those patients. To control for
the occurrence of “pocket dosing” (i.e., use of pill boxes,
removing doses for travel), patients are asked to keep
diaries of such periods, which will be accounted for in
the analyses [18]. As in other trials, an EMD will be
given to each patient to track the one antihypertensive
medication taken most frequently and instructed on its
use (without being told the primary purpose) [11, 19].
Although this does not reflect overall adherence rates,
there is evidence that the pattern of adherence to one
antihypertensive medication often reflects adherence to
others [20]. In the event that patients are prescribed
multiple medications, their PCP will be asked to identify
the primary medication to be placed in the bottle.
In addition, medication adherence to prescribed anti-
hypertensive medications is assessed with the well-
validated eight-item self-report scale developed by Mor-
isky that specifically addresses adherence to a prescribed
mediation regimen [21]. The Morisky Adherence Scale
is used to screen patients for their non-adherence during
the first month of the study. Patients who are non-
adherent at the 1-month study visit (score > 3) are con-
sidered eligible to participate. The measure has accept-
able reliability (α = 0.83), correlates well with the
previously validated 4-item version [36] (r = 0.64, p <
0.05) and was found to be able to correctly categorize
BP control status in 80 % of cases [22].
Secondary outcome
Blood pressure
The secondary outcome is the within-patient change in
SBP and DBP from baseline to 6 months. BP is assessed
using a well-validated automated device (WatchBP Of-
fice Device; Microlife; Golden, CO, USA) at all study
visits, by trained RAs who take a series of BP readings
after the patient has been seated for 5 minutes following
American Heart Association guidelines. An average of
three BP readings are used for each visit.
Self-report measures
Cognition
Cognition is assessed using the Comprehensive Assess-
ment and Referral Evaluation Dementia Diagnostic Scale
(CDIAG) [23, 24]. This instrument was selected because
it has been found to perform in a culture-fair manner
[25] with better specificity among ethnically diverse
groups, in comparison with other cognitive measures.
Patient demographic characteristics
The demographic data includes date of birth, place of
birth, years in the US, primary language spoken as a
child, primary language currently spoken at home, at
work, and with friends and family, ethnicity, gender,
household income, education level, marital status, reli-
gious affiliation, employment status, family finances,
sources of income, financial strain, health insurance sta-
tus, smoking status and alcohol use.
Comorbidity
Comorbid medical conditions are assessed with the
Charlson Comorbidity Index (CCI) [26]. The CCI is a
weighted index for prospectively classifying comorbid
conditions, which takes into account the number and
seriousness of comorbid diseases.
Illness beliefs
Illness beliefs are assessed with the Illness Perceptions
Questionnaire-revised (IPQ-R) for HTN [27]. The IPQ-
R is designed to assess the 5 illness beliefs and 6 emo-
tional reactions to HTN based on the CSM, on a 5-point
Likert type scale from strongly disagree to strongly agree
(α range: 0.79 to 0.89). The IPQ-R has demonstrated
good test-retest reliability and good predictive validity in
patients with chronic disease [28].
Health literacy
Health literacy is assessed with the 36-item short-form
Test of Functional Health Literacy in Adults (s-
TOFHLA)-Spanish [29]. The s-TOFHLA is a reading
comprehension test that has been linked to glycemic
control in Spanish-speaking and English-speaking Latino
patients with type 2 diabetes [30].
Self-efficacy
Self-efficacy is assessed with the Medication Adherence
Self-Efficacy Scale (MASES; α = 0.95) [31]. Patients are
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asked to rate their confidence in taking their antihyper-
tensive medications under a variety of situations that
may pose difficulties. Higher scores reflect high self-
efficacy.
Intrinsic motivation
Intrinsic motivation is assessed with the 14-item Treat-
ment Self-Regulation Questionnaire (TSRQ) [32]. The
TSRQ has 2 subscales: autonomous motivation and
controlled motivation (α = 0.86 for each scale).
Beliefs about Medication Questionnaire (BMQ)
The BMQ was designed to assess the patient’s personal
reasons for taking their medications [33]. Questions ask
patients to rate how much they agree or disagree about
statements that reflect their personal views about their
medicines prescribed. Responses are given on a 5-point
Likert scale (range: strongly agree to strongly disagree).
The Primary Care Assessment Survey (PCAS)
The PCAS is a 51-item patient-completed questionnaire
designed to operationalize formal definitions of primary
care including the definition posted by the Institute of
Medicine Committee on the Future of Primary Care
[34]. The survey measures 7 defining characteristics of
primary care through 11 summary scales, including de-
tailed measurement of the doctor-patient relationship
(communication quality, patient trust, physician know-
ledge of patient, interpersonal treatment, relationship
duration).
Electronic Monitoring Device (EMD) survey
Patient’s experience with the EMD will be assessed with
a 17-item questionnaire from our previous studies [18].
The first 11 questions ask about patient’s use and com-
fort with the bottle. Sample items include: “I felt com-
fortable traveling with the pill bottle” and “I used the pill
bottle every day.” Responses are given on a five-point
Likert-type scale ranging from strongly agree to strongly
disagree. The remaining six open-ended questions ask
patients about the use of a pillbox, the number of medi-
cations they lay out, and to report any problems with
the bottle.
Chart extraction data
The study staff reviews all patients’ medical records at
baseline and at 6months. Chart data extraction includes
include duration of HTN, total number and classes of
prescribed BP medications, as well as their doses and
frequencies of ingestion, changes in dosages of BP medi-
cations, frequency of clinic visits; the use of other medi-
cations known to affect BP such as NSAIDS and
hormone replacement therapy, medical comorbidity and
clinic BP readings.
Analysis
The power estimates are based on the primary aim using
the basic comparisons of number (proportion) adherent
in each group as the effect size. The nominal alpha value
is set for a 2-sided test at the α = 0.05 level. Estimates of
the hypothesized proportion of patients’ adherent in the
AI versus UC group at the final follow-up are derived
from values in the study by Lai et al. [35], the only com-
parable study with a Latino sample. Given the high pro-
portion of adherent patients in the treatment group
from that study, more conservative effect size estimates
were used for the proposed study. Thus, the projected
sample size is 148 patients (74 patients per group),
which will provide 80 % power to detect a 0.20 differ-
ence in the adherence rate for patients in the AI versus
UC groups. All analyses will be performed under an
intent-to-treat design; therefore, all patients, including
those who drop out of the study, will be invited back for
the final assessments.
While randomization is expected to produce well-
balanced groups, analyses will be done to determine any
baseline differences between the groups on demographic
or prognostic variables, using chi-square analyses for
categorical variables and analysis of variance (ANOVA)
for continuous ones. If significant differences are found
or there is scientific plausibility of an association with
the outcome variable, these variables will be included in
a logit model to predict group assignment. Data from
the initial group comparisons on patient characteristics
(including the baseline primary outcome and other pa-
tient characteristics) will also allow for the estimation of
a logit model of dropout. If the results indicate that at-
trition is significantly related to one or more baseline
characteristic, predicted values from the final logit model
will be used as a covariate in all subsequent analyses,
thereby controlling for differential attrition.
Analyses for the primary aim
The primary analysis will be a 2 (group) × 2 (adherence
status) chi-square test of independence. The expectation
is that the randomization of patients to treatment arm
and the absence of significant selection and/or attrition
biases will obviate the need for any covariates in the ana-
lysis. However, in the unlikely event that imbalances are
identified and covariates are added to the model, a gen-
eralized linear model (logistic regression) will be used. In
addition to two-sided tests of significance, the effects
will be estimated with odds ratios.
Analyses for the secondary aim
BP will be treated as continuous SBP and DBP variables
and the effect of treatment on these variables will be
assessed using linear mixed effects regression models,
with time coded based on the WatchBP date stamp and
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treatment dummy coded as 0 = UC and 1 = AI. The
critical test will be the time × treatment interaction.
Time will be treated as a random effect. Mixed effects
regression models have several advantages over trad-
itional repeated measures multivariate analysis of vari-
ance (MANOVA) models, including the ability to
include all patients in the analysis rather than only those
with complete data. The parameter estimates from the
regression models will be reported and used to calculate
predicted scores to describe the effect of the AI on these
outcomes.
Exploratory analyses
Data on the self-report measures of self-efficacy, intrin-
sic motivation, beliefs about medications, and illness
beliefs at 3 time points will allow for the examination of
these variables as possible mediators on the outcomes at
6 months. Moderating effects of acculturation and health
literacy will also be evaluated. These data may contribute
to understanding why the proposed intervention worked.
Discussion
Study implementation: challenges and lessons learned
We have encountered several “real world” barriers to
implementation of the ALMA study protocol as origin-
ally conceived. Several of the challenges we faced relate
to the difficulties involved moving away from an inter-
vention delivered by research staff to that of clinic staff
with competing priorities. This implementation model
adds a new level of complexity as researchers must con-
tend with the need to uphold the methodological rigor
of a randomized clinical trial while maintaining the
flexibility to work with staff within a busy medical prac-
tice. The two main barriers to date are patient recruit-
ment and delivery of the intervention during times that
fit both patients’ and Health Coaches’ schedules. Below,
we summarize the strategies we have employed to ad-
dress these challenges as a resource for other re-
searchers who are interested in utilizing indigenous
clinic staff for intervention delivery in community-
based practices.
Recruitment challenges
Upon initiation of the trial, we experienced several
challenges in patient recruitment. For example, we en-
countered a higher than expected rate of patient re-
fusal for study participation. The most common
reasons for declining participation include long work
schedules, inability to receive study calls while at
work, competing priorities (i.e., being too sick, caring
for a sick person), patient travel to their home country
for long periods of time, and overall lack of interest in
participating. Recruitment was also prolonged during
the first months of the study due to technical
difficulties with the wireless EMDs that were originally
selected to assess patient adherence. The main barrier
to using the wireless EMDs was the frequent disrup-
tions between the device and its communication hub,
which led to transferring incomplete data to the re-
search portal. In addition, some patients expressed dif-
ficulty in understanding how to use the device, were
dissatisfied with its use, and/or used the device incor-
rectly. The combination of these factors paired with a
higher than expected rate of physician turnover at the
clinic has prolonged patient recruitment and reduced
the overall pool of potentially eligible patients for
recruitment.
In order to mitigate these recruitment challenges,
we made several refinements to the study protocol.
First, the PCPs and their MAs select patients from a
list of potentially eligible patients identified from a
HTN registry. Once the PCPs and their MAs select
patients for the study, the patients’ appointment dates
are noted, and an introductory study postcard is sent
to inform patients of the study. Generally, this has in-
creased patients’ receptiveness to talk with the RA
during their clinical visit because it eliminates the
element of surprise by giving patients prior notice be-
fore being approached. It also helps to decrease pa-
tients’ skepticism about the study because the
postcard is endorsed by their PCP, thereby signifying
an affiliation with the clinic. Second, for patients iden-
tified via EMR searches, an ALMA sticker label is
placed on the patients’ huddle sheet to remind PCPs
and MAs of patients’ eligibility for the study. The
PCPs and/or MA can then briefly introduce the study
to eligible patients during the clinic encounter. Third,
once a patient completes the registration process, the
RA coordinates with the MA to identify the most ap-
propriate point during the visit to meet with the pa-
tient and ascertain their interest in participating in the
study. This ensures that the study staff is not disrupt-
ing the clinic workflow while trying to maximize their
reach of eligible patients. To increase visibility, adver-
tising materials are posted throughout the clinic such
as placing flyers in waiting rooms; hanging large post-
ers in exam rooms, and creating displays in the clinic’s
health showcase. Finally, we elicit additional feedback
from the clinic staff and leadership on how to best ob-
tain patient referrals and recruit patients (i.e., attend-
ing the clinic’s staff and PCP meetings periodically; a
sponsorship of a breakfast for clinic administrative
staff ) as well as hold ongoing meetings with the ACA
Board. The wireless EMD was also changed to another
model that, while not being wireless, has high accept-
ability and usage rates by the study population (EMD
return rates are as follows: 90 % at the 1-month and 3-
month visit and 92 % at the 6-month visit).
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Challenges with intervention delivery
During the formative phase, several modifications were
made to the design of the AI template embedded in the
EMR. First, based upon beta-testing with the Health
Coaches and feedback from key stakeholders, the study
team refined the design of the AI template to improve
its usability and flow during the delivery of the counsel-
ing sessions. For example, interactive features were
added such as command buttons to facilitate navigating
through the AI template and accessing the built-in EMR
goal-setting template, directly from the AI template.
Additional checkboxes containing the adherence barriers
and facilitators garnered from the focus groups were also
added to minimize the amount of note-taking and facili-
tate data collection. Finally, a comment box was added
to prevent loss of data that was not captured in the
checkboxes. These modifications improved the AI tem-
plates ease of use as well as made key data from previous
sessions easily accessible, which the Health Coaches use
to familiarize themselves with patients’ most recent
adherence behaviors.
We have also encountered several “real world” chal-
lenges to the delivery of the intervention. One of the
most frequent challenges is patients’ limited time avail-
ability to receive the counseling calls. Patients who are
employed often have a short window of availability (ap-
proximately 1–2 hours) during their work schedule to
receive the calls, and most are only available before their
workday begins or after their shift has ended; times dur-
ing which the Health Coaches are not at work. This time
barrier paired with the competing clinic duties of the
Health Coaches poses the greatest challenge to the deliv-
ery of the intervention. For these reasons, the study
protocol was modified to include having the study staff
send periodic reminder flags to the Health Coaches
(based upon Health Coaches’ request) regarding out-
standing and/or upcoming counseling sessions as well as
sending reminder postcards to patients they are unable
to reach. Additional strategies to increase intervention
attendance include: coordinating with the Health Coa-
ches who work extended rotating hours in the morning
and night (i.e., before 9:00 a.m., and after 5:00 p.m.) to
prioritize calling efforts for those patients with limited
availability; and increasing the amount of communica-
tion, as early as after the first call attempt, between the
study staff and the Health Coaches if they are unable to
reach a patient. This allows the study staff to reach pa-
tients with tight schedules beyond clinic hours and pro-
actively arrange appointments with Health Coaches.
A second “real world” challenge relates to audiotaping
the counseling sessions as a measure of treatment fidel-
ity. While, all Health Coaches were provided with audio
recorders and microphones to facilitate taping, they re-
ported not being able to comply with the recordings due
to time constraints and the need to have the equipment
stored in a location that was not readily accessible,
which hindered the recording process. As a partial solu-
tion to this challenge, Health Coaches receive numerous
booster trainings to prevent skill decay as well as to
maintain adherence to the study protocol. Moreover, the
interactive AI template in the EMR facilitates collection
of data on the content of each counseling session.
Retention challenges
Due to the patient time constraints discussed above, re-
tention strategies were also modified to facilitate the
completion of study questionnaires either on-site or over
the phone. For patients who work full-time, this de-
creased the time burden in terms of having to return to
the clinic on days when they did not have a medical ap-
pointment scheduled, or if they did not have time to
complete the visit on the day they were at the clinic. A
brief in-person visit is scheduled for patients who
complete visit surveys over the phone to take their BP.
Moreover, the assessment protocol was modified by
moving several of the questionnaires from the baseline
visit to the 1-month study visit to prevent patient fa-
tigue. The health literacy questionnaire was also moved
to the baseline visit (from the 1-month visit) in order to
facilitate the administration of the 1-month visit by
phone.
Additional strategies implemented to increase reten-
tion include: (1) mailing appointment reminder post-
cards, and/or informational postcards for patients who
are difficult to reach, or have no medical appointments
within a study visit time window to schedule the visit;
(2) updating patients’ contact information during each
study visit, and, (3) regularly checking patients’ medical
appointments to coordinate the study visits on the day
that patients are already scheduled to come to the clinic.
These changes have resulted in an overall average 87 %
retention rate at the study follow-up visits.
Trail status
The ALMA trial began in October 2012. To date, we
have randomized a total of 112 patients, of which 54 are
in the AI group and 58 are in the UC group. Patient
recruitment is still ongoing.
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